News >

Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Apr 16, 2019

Gilles A. Salles, MD, PhD
Gilles A. Salles, MD, PhD
Daratumumab (Darzalex) was associated with low overall response rates (ORRs) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma (MCL), missing the primary endpoint of a phase II trial published in Clinical Lymphoma, Myeloma & Leukemia.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication
x